# Balaji Amines share price today (Balaji Amines Ltd, NSE: BALAMINES)

> Balaji Amines share price today: ₹1,774.70 at the NSE close on 3 November 2026, up 25.9% in a year. Balaji Amines (NSE: BALAMINES) is worth ₹5,749 crore, trades at a P/E of 28.1 and has closed between ₹1,000.90 and ₹2,525.20 over the past 52 weeks. > Balaji Amines Ltd's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. BALAMINES · Chemicals - Organic · data as of 3 November 2026. Page: https://www.sectoralpha.in/stocks/balaji-amines-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Turning around, from fewer quarters than usual
- Price: ₹1,774.70 (+25.9% in a year)
- P/E: 28.1× (higher than 65% of the last 11 years)
- Revenue (Jun 2026): ₹456 Cr (+27.4% on a year ago)
- Profit (Jun 2026): ₹78.0 Cr (+110.8% on a year ago)
- Operating margin: 25.0% (+10.0 points on a year ago)
- ROCE: 11%, FY26
- Profit that came in as cash: 138%, last 3 years

The main question: foreign institutions moved −2.0 percentage points over 8 quarters while the business went the other way. ## What is the Balaji Amines share price today? Balaji Amines Ltd's share price was ₹1,774.70 at the close on 3 November 2026. It has been rising for 23 weeks. That is 4.6% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹1,001 and ₹2,525, and at that close it sat 51% of the way up from that low. Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 6 weeks running. Over the last 11 years the share price moved +1,216% while the NIFTY 500 moved +251%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 28 September 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Balaji Amines this quarter? Three changes stood out: best operating margin in 15 quarters, highest quarterly profit in 14 quarters and highest quarterly revenue in 12 quarters. 1. Best operating margin in 15 quarters Operating margin was 25% in the June 2026 quarter, against 15% a year earlier. 2. Highest quarterly profit in 14 quarters Profit of ₹78 crore in the June 2026 quarter is the highest of the last 14 quarters. 3. Highest quarterly revenue in 12 quarters Revenue of ₹456 crore in the June 2026 quarter is the highest of the last 12 quarters. ## What are Balaji Amines' latest quarterly results? For April to June 2026 (the quarter ended 30 June 2026), Balaji Amines reported revenue of ₹456 crore, up 27.4% from ₹358 crore a year earlier, and a profit of ₹78.0 crore, up 110.8% from ₹37.0 crore. ### Balaji Amines results: April to June 2026 against a year earlier

| Measure | April to June 2026 | April to June 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹456 crore | ₹358 crore | +27.4% |
| Profit | ₹78.0 crore | ₹37.0 crore | +110.8% |
| Earnings per share | ₹23.13 | ₹11.73 | +97.2% |
| Operating margin | 25.0% | 15.0% | +10.0 points |

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). The newest call in our records is from 18 May 2026, about January to March 2026; a call about these results is not in our records yet. (From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.)

## What is the Balaji Amines share price history? Balaji Amines closed at ₹1,774.70 on 3 November 2026, up 25.9% from ₹1,409.10 a year earlier (31 October 2025) and down 48.6% over five years. Its highest weekly close since March 2016 was ₹4,780.95 on 17 September 2021. ### Balaji Amines share price: then and now

| When | Close | Change to 3 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 23 Oct 2026 | ₹1,827.90 | −2.9% |
| 1 month ago · 1 Oct 2026 | ₹2,052.20 | −13.5% |
| 6 months ago · 30 Apr 2026 | ₹1,333.65 | +33.1% |
| 1 year ago · 31 Oct 2025 | ₹1,409.10 | +25.9% |
| 3 years ago · 3 Nov 2023 | ₹2,041.70 | −13.1% |
| 5 years ago · 4 Nov 2021 | ₹3,453.00 | −48.6% |
| 10 years ago · 4 Nov 2016 | ₹351.15 | +405.4% |
| Earliest and lowest weekly close in our records · 11 Mar 2016 | ₹134.90 | +1,215.6% |
| Highest weekly close since March 2016 · 17 Sep 2021 | ₹4,780.95 | −62.9% |
| 52-week high (weekly close) · 4 Sep 2026 | ₹2,525.20 | −29.7% |
| 52-week low (weekly close) · 13 Mar 2026 | ₹1,000.90 | +77.3% |

Weekly closing prices. Each change is the move from that price to the 3 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (564 weekly closes from 11 March 2016 to 3 November 2026.)

## What is the latest news on Balaji Amines? 3 Nov 2026: Balaji Amines closed at ₹1,774.70, down 2.9% on the week and down 13.5% on the month. 3 Jul 2026: ex-date for a dividend of ₹11 a share. ### Earlier

- Results for April to June 2026: Revenue up 27.4% and profit up 110.8% on a year earlier. - 18 May 2026: Balaji Amines held its results call for January to March 2026. Management guided: Consolidated volume growth 25-30% by end FY27 from current run-rate. ## What dividend does Balaji Amines pay? Balaji Amines paid ₹11 a share in regular dividends in the 12 months to 4 November 2026 (1 payment), a yield of 0.62% at the ₹1,774.70 close on 3 November 2026. The last was a dividend of ₹11 a share, ex-date 3 July 2026. ### Balaji Amines dividends since 1 April 2021

| Ex-date | Dividend per share | Type |
| --- | --- | --- |
| 3 Jul 2026 | ₹11 | Dividend |
| 1 Aug 2025 | ₹11 | Dividend |
| 4 Jul 2024 | ₹11 | Dividend |
| 3 Jul 2023 | ₹10 | Dividend |
| 21 Jun 2022 | ₹6 | Dividend |
| 29 Jul 2021 | ₹4 | Dividend |

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. The record date is the same day as the ex-date for every payment here. 5 of 5 Of the last 5 financial years, years with an NSE dividend record

Yes. Balaji Amines Ltd paid out 21% of its profit as dividends in FY26, and it paid a dividend in each of its last 13 reported years. (From the NSE corporate-actions record, read 4 November 2026.)

## What did Balaji Amines management say on the latest results call? On the call for January to March 2026, held on 18 May 2026, Balaji Amines' management guided: Consolidated volume growth 25-30% by end FY27 from current run-rate. > “We should see minimum 25 to 30 percent volume growth by FY27 end from current volumes, with EBITDA sustainable between 22 to 23 percent on total sales”
> Management D. Ram Reddy, on the call for January to March 2026

### What management guided

- Operating margin 22-23% sustainable on total sales going forward. - FY27 volume growth 10-15% consolidated (conservative baseline) to account for new-product ramp delays and customer trials; volume front-loading expected post-ramp once product stabilization complete. - DME utilization: 30-40% in FY27, ramping 50-60% by year-end, then 80-90% in subsequent years; full capacity 1 lakh TPA with ₹80-100 pricing yields ₹640-720 crore revenue potential at 80% utilization. - Consolidated capital spending FY27 ₹275-290 crore: standalone ₹20 crore balance (DME/NMM/ACN), BSC ₹250-275 crore. Management’s own plans and goals, from our notes of the call. A plan is not a result. Source: [the call transcript](https://files.tijorifinance.com/insight/india/3481/Conference Call/CC-May26.pdf). (From the call for January to March 2026, 18 May 2026. The April to June 2026 results are out since, so this part may be out of date until we update it.)

## What to watch in Balaji Amines' next results? When Balaji Amines reports July to September 2026, these are the 4 checks that show whether the story is still on course. First: DME road transport approval expected within ~1 month per management - critical gate for commercial supply commencement; if delayed beyond guided timeline, April to June 2026 production and revenue completely deferred; next call to flag approval status and production ramp trajectory. - What to check (from the call)
- DME road transport approval expected within ~1 month per management - critical gate for commercial supply commencement; if delayed beyond guided timeline, April to June 2026 production and revenue completely deferred; next call to flag approval status and production ramp trajectory. - DME trial-to-bulk-order conversion rate in H1 FY27 - 100 cylinders of 500kg each in customer distribution for testing; bulk order quantum, timing, and customer names critical to validating commercial demand foundation; next call to report trial completion status and letters of intent / commercial orders received. - BSC Unit 1 brownfield profitability post-H1 FY27 commissioning - first specialty chemical asset to go live and critical to validating 22-23% operating profit guidance and import-substitution thesis; gross margin recovery vs FY26 compression essential; management flagged real figures opaque until Q3 onwards. - Consolidated volume growth FY27 actual vs 10-15% conservative guidance - quarterly volumes relative to 10-15% baseline will indicate new-product ramp acceleration trajectory and revised full-year run-rate expectations; miss vs guidance signals execution risk; monitor against production and order intake disclosures. ## Which stock lists is Balaji Amines on? Balaji Amines is not on any of our India lists this week. ## Is Balaji Amines profitable? Balaji Amines Ltd earned ₹78.0 Cr of net profit in the Jun 2026 quarter, +110.8% on the same quarter a year earlier. That is the 2nd quarter in a row of profit growth. Full-year FY26 profit was ₹169 Cr. Over 10 years profit has grown 11.3% a year on average. That is 17.1% of the quarter's revenue. The same quarter a year earlier earned ₹37.0 Cr. For the full year, FY26 profit was ₹169 Cr (+6.3% on the year before). Why profit moved: revenue changed +27.4% on a year earlier and the margin moved +10.0 percentage points. Most of the change came from keeping more of each sale. On average over the last four quarters, profit changed +40.9% and revenue +10.8%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit. ## How much revenue does Balaji Amines make, and is it growing? Balaji Amines Ltd reported ₹456 Cr of revenue in the Jun 2026 quarter, +27.4% on the same quarter a year earlier. That is the 3rd quarter in a row with growth on the year before. Over 10 years it has grown 8.3% a year on average. The last full year, FY26, came in at ₹1,419 Cr. The last four reported quarters add to ₹1,523 Cr. FY26 revenue was ₹1,419 Cr, +2.2% on the year before. Recent pace: the last four quarters grew +10.8% on average, against 8.3% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +11.1%, against −1.3% a year over the last 8 quarters (accelerating); profit over the last 12 months grew +41.6%, against +0.2% a year (accelerating). ## How much of every ₹100 of sales does Balaji Amines keep? Balaji Amines Ltd's operating margin was 25.0% in the Jun 2026 quarter, 10.0 percentage points higher than the same quarter a year ago. Across 13 years it has been between 15.0% and 29.0%. The latest quarter is within that range. Why the margin moved: operating margin changed +10.2 percentage points on the year while gross margin changed +3.7 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is Balaji Amines' profit turning into cash? Over the last 3 years, 138% of Balaji Amines Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹184 Cr of operating cash against ₹169 Cr of profit. After ₹370 Cr of spending on assets, free cash was −₹186 Cr: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 138% of profit came in as cash: the cash cycle got 59 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives. What to look at next: the bigger use of cash is spending on new assets, at 5.4× depreciation over three years. The next section checks what that spending is building. ## Where does Balaji Amines' cash go? Balaji Amines Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 163 days in FY26, up from 104 days in FY21. It spent ₹811 Cr on assets over the last 3 years. Customers take 89 days to pay, and stock sits for 113 days on average. At FY26 sales of ₹1,419 Cr, each day of that cycle ties up about ₹3.9 Cr, so roughly ₹634 Cr is tied up in the business at any time. FY26: customers took 89 days to pay and stock sat for 113 days, about 3.7 months of sales sitting as stock, for a full cycle of 163 days, longer than FY21's 104. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 113 days. Customers pay about 89 days after that. Suppliers are paid at 39 days. Together that makes the 163-day cycle. Spending on assets: ₹811 Cr over the last 3 years, against ₹149 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹512 Cr (FY26): assets paid for that are not earning yet. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Balaji Amines' P/E ratio, and how does it compare with its own history? Balaji Amines Ltd's P/E is 28.1×, in the middle of its own history: higher than 65% of past readings. Its usual P/E (the middle reading) is 24.0×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved +6.1% while the price moved +25.9%. The price did better than earnings, which pushed the multiple up within its own range. Where the price move came from: over 5 years the price moved −12.5% a year; about −9.1% a year came from earnings growth and about −3.4 percentage points from the multiple (the market paying less); over 10 years the price moved +17.6% a year; about +13.5% a year came from earnings growth and about +4.1 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple. The PEG ratio and its quarterly curve, which only the second data source has, are not shown on this page: its two data sources disagree by up to 25% on reported income across 15 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data. ## Is the Balaji Amines business getting better or worse? Balaji Amines Ltd's business is turning around. Profit growth has swung from −31.9% at its low to +41.6%, improving for 4 quarters in a row, with ROCE falling at 11.0%. This is based on 8 quarters of 4 measures, with some gaps. Why it matters: a turn in growth is often where a bigger change starts. The lines say a turn is forming, so the question is whether the next quarters confirm it. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. This reading has some gaps: at least one line is short, or the return line is not the quarterly series, so treat it with a little more caution. ## How much does Balaji Amines earn on its capital? Balaji Amines Ltd earned a ROCE of 11% in FY26. We cannot compare its return on capital used with its cost of capital from the data we have. It comes from a 11.9% net margin and 0.52× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 11.9% net margin × 0.52× asset turnover × 1.39× leverage (assets divided by equity) ≈ 8.6% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed. The quarterly return lines and the return-on-capital-used (ROIC) line, which only the second data source has, are not shown on this page: its two data sources disagree by up to 25% on reported income across 15 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data. ## Does Balaji Amines have too much debt? Balaji Amines Ltd had ₹133 Cr of borrowings against ₹1,976 Cr of equity in FY26, so its debt is 0.07× its equity. Its operating profit is 53 times its interest bill. Over 5 years borrowings went from ₹127 Cr to ₹133 Cr. Over the last 3 of those years it spent ₹811 Cr on assets. Part of the spending on assets is being paid for with borrowed money. The total-debt and debt-to-equity series, which only the second data source has, are not shown on this page: its two data sources disagree by up to 25% on reported income across 15 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data. ## What is the Balaji Amines shareholding pattern? Foreign institutions cut their stake in Balaji Amines Ltd by 2.0 percentage points over 8 quarters, the biggest change among its owners. Foreign institutions now own 3.3% of the company. Promoters moved +0.9 points over the same period, to 54.6%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Foreign institutions: −2.0 points over 8 quarters, to 3.3%; Promoters: +0.9 points over 8 quarters, to 54.6%; Domestic institutions: −0.3 points over 8 quarters, to 1.5%. Why the owners changed: foreign institutions drove it (−2.0 points), with the other side taken by promoters (+0.9 points). They reduced their stake. ## How far is Balaji Amines from balance-sheet trouble? For Balaji Amines Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Balaji Amines rank in its industry? 53.6 out of 100, rank 9 of 20 in Chemicals - Organic, with 78% of the evidence available. Balaji Amines Ltd scores 53.6 out of 100 against the 20 companies it is compared with in Chemicals - Organic, ranking 9. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 23.2 + 13.1 + 9.1 + 8.2 = 53.6. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Balaji Amines compared with? Balaji Amines ranks 9 of 20 Chemicals - Organic companies on the 4-Factor Sector Score, with 53.6 out of 100. 1. [Nitta Gelatin India Ltd](https://www.sectoralpha.in/stocks/nitta-gelatin-india-ltd) NITTAGELA · quiet · Most evidence points up · 85% evidence 76.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.4/35 · Revenue 15% · Profit 49.4% · Operating margin change 9 points · 100% evidence Capital efficiency 21.3/25 · ROCE 27.7% · Operating margin 28% · 100% evidence Valuation 13.2/20 · P/E 12.1× · PEG 0.95 · 100% evidence Relative strength 12.0/20 · Lead over its industry n/a · Lead over NIFTY 500 35.5% · 1 year n/a · 25% evidence · 5 of 12 weeks ahead Exact sum: 30.4 + 21.3 + 13.2 + 12 = 76.9 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [Indo Amines Ltd](https://www.sectoralpha.in/stocks/indo-amines-ltd) INDOAMIN · losing its lead · Most evidence points up · 81% evidence 66.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.8/35 · Revenue 13.3% · Profit 24.2% · Operating margin change 3 points · 88% evidence Capital efficiency 16.8/25 · ROCE 18.9% · Operating margin 14% · 100% evidence Valuation 19.0/20 · P/E 10.6× · PEG 0.32 · 100% evidence Relative strength 9.5/20 · Lead over its industry n/a · Lead over NIFTY 500 2.3% · 1 year -10.4% · 25% evidence · 4 of 12 weeks ahead Exact sum: 20.8 + 16.8 + 19 + 9.5 = 66.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 3. [Valiant Organics Ltd](https://www.sectoralpha.in/stocks/valiant-organics-ltd) VALIANTORG · breaking out · Evidence leans up · 78% evidence 61.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.4/35 · Revenue 1.5% · Profit 100% · Operating margin change 6 points · 83% evidence Capital efficiency 9.0/25 · ROCE 5.5% · Operating margin 18% · 76% evidence Valuation 10.9/20 · P/E 23.2× · PEG n/a · 50% evidence Relative strength 19.8/20 · Lead over its industry 24.1% · Lead over NIFTY 500 48.6% · 1 year 39.6% · 100% evidence · 10 of 12 weeks ahead Exact sum: 21.4 + 9 + 10.9 + 19.8 = 61.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [OCCL Ltd](https://www.sectoralpha.in/stocks/occl-ltd) OCCLLTD · breaking out · Too little evidence to rank firmly · 56% evidence 59.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.6/35 · Revenue 40.6% · Profit 100% · Operating margin change 7 points · 83% evidence Capital efficiency 12.3/25 · ROCE 13% · Operating margin 28% · 76% evidence Valuation 11.1/20 · P/E 11× · PEG n/a · 15% evidence Relative strength 12.1/20 · Lead over its industry n/a · Lead over NIFTY 500 45.3% · 1 year n/a · 25% evidence · 12 of 12 weeks ahead Exact sum: 23.6 + 12.3 + 11.1 + 12.1 = 59.1 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 5. [BASF India Ltd](https://www.sectoralpha.in/stocks/basf-india-ltd) BASF · quiet · Evidence leans up · 71% evidence 57.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.8/35 · Revenue 6.5% · Profit 62.4% · Operating margin change 4 points · 88% evidence Capital efficiency 11.7/25 · ROCE 14.5% · Operating margin 10% · 100% evidence Valuation 14.1/20 · P/E 21.4× · PEG n/a · 50% evidence Relative strength 7.7/20 · Lead over its industry n/a · Lead over NIFTY 500 -13% · 1 year -30.9% · 25% evidence · 5 of 12 weeks ahead Exact sum: 23.8 + 11.7 + 14.1 + 7.7 = 57.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Elantas Beck India Ltd](https://www.sectoralpha.in/stocks/elantas-beck-india-ltd) ELANTAS · leader · Evidence leans up · 67% evidence 57.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.7/35 · Revenue 18.7% · Profit 35.5% · Operating margin change 1 points · 95% evidence Capital efficiency 18.1/25 · ROCE 21.2% · Operating margin 23% · 76% evidence Valuation 6.5/20 · P/E 54.1× · PEG n/a · 50% evidence Relative strength 11.8/20 · Lead over its industry n/a · Lead over NIFTY 500 31.9% · 1 year 33.1% · 25% evidence · 12 of 12 weeks ahead Exact sum: 20.7 + 18.1 + 6.5 + 11.8 = 57.1 · What this means: A strong business with a high valuation: it would need rising earnings, or a lower multiple, to score better on value. 7. [Fine Organic Industries Ltd](https://www.sectoralpha.in/stocks/fine-organic-industries-ltd) FINEORG · leader · Evidence leans up · 96% evidence 56.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 13.9/35 · Revenue 7.1% · Profit 5.8% · Operating margin change 4 points · 88% evidence Capital efficiency 17.8/25 · ROCE 21.5% · Operating margin 25% · 100% evidence Valuation 15.0/20 · P/E 35.3× · PEG 0.58 · 100% evidence Relative strength 9.9/20 · Lead over its industry -7.6% · Lead over NIFTY 500 12.4% · 1 year 13.8% · 100% evidence · 9 of 12 weeks ahead Exact sum: 13.9 + 17.8 + 15 + 9.9 = 56.6 · What this means: The valuation scores well, but earnings are not improving yet, so the business does not back up the low multiple so far. 8. [Laxmi Organic Industries Ltd](https://www.sectoralpha.in/stocks/laxmi-organic-industries-ltd) LXCHEM · quiet · Evidence leans up · 81% evidence 54.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.1/35 · Revenue 5.5% · Profit 26% · Operating margin change 7.6 points · 88% evidence Capital efficiency 10.8/25 · ROCE 4.7% · Operating margin 12% · 100% evidence Valuation 13.1/20 · P/E 33.8× · PEG 1.14 · 100% evidence Relative strength 9.2/20 · Lead over its industry n/a · Lead over NIFTY 500 1.8% · 1 year -22% · 25% evidence · 10 of 12 weeks ahead Exact sum: 21.1 + 10.8 + 13.1 + 9.2 = 54.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 9. Balaji Amines Ltd this page BALAMINES · quiet · Evidence leans up · 78% evidence 53.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.2/35 · Revenue 11.1% · Profit 41.6% · Operating margin change 10 points · 83% evidence Capital efficiency 13.1/25 · ROCE 11% · Operating margin 25% · 76% evidence Valuation 9.1/20 · P/E 28× · PEG n/a · 50% evidence Relative strength 8.2/20 · Lead over its industry -2.5% · Lead over NIFTY 500 15.2% · 1 year 25.3% · 100% evidence · 6 of 12 weeks ahead Exact sum: 23.2 + 13.1 + 9.1 + 8.2 = 53.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 10. [Fairchem Organics Ltd](https://www.sectoralpha.in/stocks/fairchem-organics-ltd) FAIRCHEMOR · quiet · Evidence leans up · 100% evidence 53.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.3/35 · Revenue 17.1% · Profit 100% · Operating margin change 6.2 points · 100% evidence Capital efficiency 7.0/25 · ROCE 3.3% · Operating margin 10% · 100% evidence Valuation 13.0/20 · P/E 32.7× · PEG 0.84 · 100% evidence Relative strength 3.0/20 · Lead over its industry -15.4% · Lead over NIFTY 500 3.2% · 1 year -15.9% · 100% evidence · 9 of 12 weeks ahead Exact sum: 30.3 + 7 + 13 + 3 = 53.3 · What this means: Earnings are strong; relative strength in its sector is -15.4% and the one-year return is -15.9%. 11. [Sigachi Industries Ltd](https://www.sectoralpha.in/stocks/sigachi-industries-ltd) SIGACHI · breaking out · Evidence leans down · 100% evidence 49.4 out of 100 Growth Capital Valuation Relative
12. [GFL Ltd](https://www.sectoralpha.in/stocks/gfl-ltd) GFLLIMITED · breaking out · Evidence leans down · 71% evidence 48.6 out of 100 Growth Capital Valuation Relative
13. [Jyoti Resins and Adhesives Ltd](https://www.sectoralpha.in/stocks/jyoti-resins-and-adhesives-ltd) JYOTIRES · basing · Evidence leans down · 74% evidence 43.7 out of 100 Growth Capital Valuation Relative
14. [Foseco India Ltd](https://www.sectoralpha.in/stocks/foseco-india-ltd) FOSECOIND · leader · Evidence leans down · 81% evidence 41.1 out of 100 Growth Capital Valuation Relative
15. [Shree Ganesh Remedies Ltd](https://www.sectoralpha.in/stocks/shree-ganesh-remedies-ltd) SGRL · breaking out · Evidence leans down · 85% evidence 40.3 out of 100 Growth Capital Valuation Relative
16. [Oriental Aromatics Ltd](https://www.sectoralpha.in/stocks/oriental-aromatics-ltd) OAL · leader · Evidence leans down · 74% evidence 36.5 out of 100 Growth Capital Valuation Relative
17. [Gem Aromatics Ltd](https://www.sectoralpha.in/stocks/gem-aromatics-ltd) GEMAROMA · quiet · Too little evidence to rank firmly · 51% evidence 32.2 out of 100 Growth Capital Valuation Relative
18. [Sacheerome Ltd](https://www.sectoralpha.in/stocks/sacheerome-ltd) SACHEEROME · losing its lead · Too little evidence to rank firmly · 36% evidence 58.1 out of 100 Growth Capital Valuation Relative
19. [Shri Ahimsa Naturals Ltd](https://www.sectoralpha.in/stocks/shri-ahimsa-naturals-ltd) SHRIAHIMSA · leader · Too little evidence to rank firmly · 47% evidence 56.8 out of 100 Growth Capital Valuation Relative
20. [Citurgia Biochemicals Ltd](https://www.sectoralpha.in/stocks/citurgia-biochemicals-ltd) CITURGIA · Too little evidence to rank firmly · 25% evidence 34.3 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Chemicals - Organic](https://www.sectoralpha.in/sectors/chemicals-organic), all 20 compared on one page. ## Which companies are close to Balaji Amines in size? Balaji Amines is the 4th largest of 20 Chemicals - Organic companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Fine Organic Industries, BASF India and Elantas Beck India. Just below it: Foseco India, Laxmi Organic Industries and Oriental Aromatics. ### Chemicals - Organic companies close in size

1. [Fine Organic Industries Ltd](https://www.sectoralpha.in/stocks/fine-organic-industries-ltd) ₹15,480 crore
2. [BASF India Ltd](https://www.sectoralpha.in/stocks/basf-india-ltd) ₹13,198 crore
3. [Elantas Beck India Ltd](https://www.sectoralpha.in/stocks/elantas-beck-india-ltd) ₹6,417 crore
4. Balaji Amines Ltd ₹5,721 crore
5. [Foseco India Ltd](https://www.sectoralpha.in/stocks/foseco-india-ltd) ₹4,419 crore
6. [Laxmi Organic Industries Ltd](https://www.sectoralpha.in/stocks/laxmi-organic-industries-ltd) ₹4,245 crore
7. [Oriental Aromatics Ltd](https://www.sectoralpha.in/stocks/oriental-aromatics-ltd) ₹1,916 crore

[All 20 Chemicals - Organic companies, largest first](https://www.sectoralpha.in/sectors/chemicals-organic#all-companies)

### Companies close in size in other industries

1. [Sun Pharma Advanced Research Company Ltd](https://www.sectoralpha.in/stocks/sun-pharma-advanced-research-company-ltd) ₹5,727 crore · Pharma - Others
2. [Redtape Ltd](https://www.sectoralpha.in/stocks/redtape-ltd) ₹5,724 crore · Footwear
3. Balaji Amines Ltd ₹5,721 crore
4. [Mrugesh Trading Ltd](https://www.sectoralpha.in/stocks/mrugesh-trading-ltd) ₹5,710 crore · NBFC - Others
5. [Transrail Lighting Ltd](https://www.sectoralpha.in/stocks/transrail-lighting-ltd) ₹5,695 crore · EPC

## What else do people ask about Balaji Amines? ### What is Balaji Amines's share price today? Balaji Amines Ltd's share price is ₹1,774.70, +25.9% over the past year. The whole company is worth ₹5,749 Cr on the market. In the last 52 weeks it traded between ₹1,001 to ₹2,525; today it is 51% of the way up from the low, 4.6% below its 200-day average (as of 3 November 2026). ### What were Balaji Amines's latest quarterly results? Balaji Amines Ltd reported revenue of ₹456 Cr and net profit of ₹78.0 Cr for the Jun 2026 quarter. Revenue rose 27.4% and profit rose 110.8% compared with a year earlier. Earnings per share were ₹23.13. The operating margin was 25.0%, 10.0 percentage points higher than a year earlier (as of 3 November 2026). ### What is Balaji Amines's market cap? Balaji Amines Ltd's market capitalisation is ₹5,749 Cr at a share price of ₹1,774.70. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Balaji Amines performing? Balaji Amines Ltd's share price has been rising for 23 weeks. In its latest quarter, revenue rose 27.4% and profit rose 110.8% compared with a year earlier. Over the past 13 weeks it has done worse than the NIFTY 500, for 6 weeks running (as of 3 November 2026). ### Will Balaji Amines's share price go up? This page does not forecast Balaji Amines Ltd's share price. What it shows instead: the share price is ₹1,774.70, and it has been rising for 23 weeks. Its P/E of 28.1× is higher than 65% of its own last 11 years (as of 3 November 2026). ### Who owns Balaji Amines? Promoters own 54.6% of Balaji Amines Ltd, foreign institutions 3.3%, domestic institutions 1.5% and the public 40.7% (latest quarter). The biggest change over the last two years: Foreign institutions cut their stake by 2.0 percentage points over 8 quarters (as of 3 November 2026). ### Where is Balaji Amines in its business cycle? Balaji Amines Ltd's FY26 operating margin was 19.0%, against a 13-year range of 15.0% to 29.0%: the middle of its own range, neither a peak nor a low. The latest quarter was 25.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Balaji Amines story? The main question: foreign institutions moved −2.0 percentage points over 8 quarters while the business went the other way. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Balaji Amines a stock worth studying right now? What the numbers show: Balaji Amines Ltd's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: whether the owners’ moves turn back in line with the business. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). ### Is there a Balaji Amines share price forecast for 2026? What management itself guided: Consolidated volume growth 25-30% by end FY27 from current run-rate. This is research, not advice. We’re not SEBI-registered.